Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | LAP3 | P28838 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5490955 | 0.84 | SLC7A5 (0.44) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL28625915 | 0.75 | — | — | |
| SCHEMBL2785568 | 0.75 | SLC7A5 (0.55) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL29287703 | 0.73 | ELANE (0.30) | — | |
| SCHEMBL27932393 | 0.72 | SLC7A5 (0.52) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL288204 | 0.72 | SLC7A5 (0.52) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL10530419 | 0.72 | SLC7A5 (0.52) | SLC7A5DPP4FAPDPP8DPP9 | |
| SCHEMBL23455917 | 0.70 | — | — | |
| SCHEMBL135981 | 0.70 | — | — | |
| SCHEMBL20750937 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5683867-A | NUCLEIC ACID LIGANDS, BLENDING, PARTITIONING AND AMPLIFICATION | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-11-04 | — | — | US | claimed |
| US-20070134715-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: BLENDED SELEX | GILEAD SCIENCES, INC. (US) | 2007-06-14 | — | — | US | disclosed |
| EP-1793006-A2 | Nucleic acid ligands and improved methods for producing the same | GILEAD SCIENCES, INC. (US) | 2007-06-06 | — | — | EP | disclosed |
| US-7176295-B2 | Systematic evolution of ligands by exponential enrichment: blended SELEX | GILEAD SCIENCES, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060088877-A1 | Systematic evolution of ligands by exponential enrichment: Chemi-SELEX | GILEAD SCIENCES, INC. (US) | 2006-04-27 | — | — | US | disclosed |
| EP-0840742-A4 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: CHEMI-SELEX | NEXSTAR PHARMACEUTICALS INC (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20030186231-A1 | Systematic evolution of ligands by exponential enrichment: Chemi-ESLEX | GILEAD SCIENCES, INC. | 2003-10-02 | — | — | US | disclosed |
| EP-0724647-A4 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | GILEAD SCIENCES INC (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030077646-A1 | Systematic evolution of ligands by exponential enrichment: blended SELEX | GILEAD SCIENCES, INC. (US) | 2003-04-24 | — | — | US | disclosed |
| US-6465189-B1 | PARTITIONING AND REPLICATING INCREASED AFFINITY BLENDED NUCLEIC ACIDS; DEVELOPMENT OF ELASTASE INHIBITORS; MEDICAL DIAGNOSIS OF RESPIRATORY SYSTEM, GENETIC, AND RHEUMATIC DISORDERS | GILEAD SCIENCES, INC. | 2002-10-15 | — | — | US | disclosed |
| US-6083696-A | DETECTION OF BLENDED NUCLEIC ACID LIGANDS OF A TARGET COMPOUND; INCUBATION OF BLENDED NUCLEIC ACID MIXTURE WITH THE TARGET, SEPARATING BLENDED NUCLEIC ACIDS WITH INCREASED RECEPTIVITY, AMPLIFYING BLENDED NUCLEIC ACIDS | NEXSTAR PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| US-5998142-A | NUCLEIC ACID LIGAND WHICH BINDS TO PROTEIN | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-12-07 | — | — | US | disclosed |
| US-5962219-A | DETECTING NUCLEIC ACIDS WITH ACTIVITY BY MIXING WITH TARGET, FORMING COVALENT BOND BETWEEN TARGET AND CHEMICALLY REACTIVE UNIT OF NUCLEIC ACID, SEPARATING NUCLEIC ACIDS WITH ACTIVITY FROM NONREACTIVE NUCLEIC ACIDS | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5871924-A | METHOD FOR IDENTIFYING AND PREPARING NUCLEIC ACID LIGANDS CAPABLE OF FACILITATING AMINOACYL-RNA SYNTHESIS | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| EP-0840742-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: CHEMI-SELEX | NeXstar Pharmaceuticals, Inc. (US) | 1998-05-13 | — | — | EP | disclosed |
| US-5705337-A | NUCLEIC ACID DETECTION OF LIGANDS THAT BIND COVALENTLY WITH TARGET MOLECULE COMPLEXES | NEXSTAR PHARMACEUTICALS, INC. (US) | 1998-01-06 | — | — | US | disclosed |
| US-5683867-A | NUCLEIC ACID LIGANDS, BLENDING, PARTITIONING AND AMPLIFICATION | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-11-04 | — | — | US | disclosed |
| WO-1996027605-A1 | SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT: CHEMI-SELEX | NEXSTAR PHARMACEUTICALS, INC. (US) | 1996-09-12 | — | — | WO | disclosed |
| EP-0724647-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NeXstar Pharmaceuticals, Inc. (US) | 1996-08-07 | — | — | EP | disclosed |
| WO-1995007364-A1 | NUCLEIC ACID LIGANDS AND IMPROVED METHODS FOR PRODUCING THE SAME | NEXSTAR PHARMACEUTICALS, INC. (US) | 1995-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060088877-A1 | Systematic evolution of ligands by exponential enrichment: Chemi-SELEX | CLASP1, PCNA, DCLRE1B | SLC7A5 2068/4885DPP4 3278/4885FAP 3318/4885 |
| US-20030186231-A1 | Systematic evolution of ligands by exponential enrichment: Chemi-ESLEX | CLASP1, DCLRE1B, PCNA | SLC7A5 1786/4885DPP4 3043/4885FAP 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.